These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31473111)

  • 1. Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: An open-label, randomized study.
    Oi I; Ito I; Tanabe N; Konishi S; Hamao N; Yasutomo Y; Kadowaki S; Hirai T
    J Infect Chemother; 2020 Feb; 26(2):181-187. PubMed ID: 31473111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.
    Ito I; Kadowaki S; Tanabe N; Haruna A; Kase M; Yasutomo Y; Tsukino M; Nakai A; Matsumoto H; Niimi A; Chin K; Ichiyama S; Mishima M
    Pulm Pharmacol Ther; 2010 Oct; 23(5):403-10. PubMed ID: 20561917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
    Hamao N; Ito I; Konishi S; Tanabe N; Shirata M; Oi I; Tsukino M; Matsumoto H; Yasutomo Y; Kadowaki S; Hirai T
    BMC Pulm Med; 2020 Jun; 20(1):160. PubMed ID: 32503515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients.
    Tokuyasu H; Harada T; Watanabe E; Okazaki R; Touge H; Kawasaki Y; Shimizu E
    Intern Med; 2009; 48(3):129-35. PubMed ID: 19182422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
    Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
    J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of i.v. push administration on β-lactam pharmacodynamics.
    Butterfield-Cowper JM; Burgner K
    Am J Health Syst Pharm; 2017 May; 74(9):e170-e175. PubMed ID: 28438821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections.
    Badaró R; Molinar F; Seas C; Stamboulian D; Mendonça J; Massud J; Nascimento LO;
    Braz J Infect Dis; 2002 Oct; 6(5):206-18. PubMed ID: 12495602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime/clindamycin vs. ceftriaxone/clindamycin for the empiric treatment of poisoned patients with aspiration pneumonia.
    Talaie H; Jabari HR; Shadnia S; Pajouhmand A; Nava-Ocampo AA; Youssefi M
    Acta Biomed; 2008 Aug; 79(2):117-22. PubMed ID: 18788506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of early switch from intravenous to oral antimicrobials in patients with aspiration pneumonia: A prospective observational study.
    Uni M; Nishimura N; Yamano Y; Ishikawa G; Kitamura A; Tomishima Y; Jinta T; Takahashi O; Deshpande G; Chohnabayashi N
    Respir Investig; 2015 Sep; 53(5):225-31. PubMed ID: 26344612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial.
    Cordero E; Bouza E; Ruiz I; Pachon J
    J Antimicrob Chemother; 2001 Oct; 48(4):527-34. PubMed ID: 11581232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of twice a day and three times a day meropenem administration in elderly patients in a Japanese community hospital.
    Aimiya K; Mamiya T; Tabuchi K; Kita T; Hiramatsu M
    Nagoya J Med Sci; 2018 Aug; 80(3):391-400. PubMed ID: 30214088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
    Paladino JA; Eubanks DA; Adelman MH; Schentag JJ
    J Am Geriatr Soc; 2007 May; 55(5):651-7. PubMed ID: 17493183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
    Liu JW; Chen YH; Lee WS; Lin JC; Huang CT; Lin HH; Liu YC; Chuang YC; Tang HJ; Chen YS; Ko WC; Lu MC; Wang FD
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.